Building the AI Business Case in Pharma: What Leadership Needs to See

Why Pharma AI Business Cases Fail at the Executive Table

If you’ve watched promising AI use cases die during steering committee review, you’ve seen the same patterns repeat. The technical team built something that works. The pilot results look encouraging. The next stage funding decision arrives, and the case quietly evaporates.

The failure modes are remarkably consistent. The first is what we call metric mismatch — the team presents efficiency gains (hours saved, documents processed) when the executive audience needs strategic outcomes (cycle time, decision quality, regulatory risk). The second is opaque risk framing — the proposal acknowledges risks at a high level but doesn’t quantify them in language the Quality and Compliance functions can engage with. The third is weak comparators — the case compares the AI-enabled process to the current manual process when the executive comparison is between alternative AI investments competing for the same budget.

None of these failure modes are about the AI itself. They are failures of business case construction — and they are correctable.

The Stakeholder Map: What Each Audience Needs

Pharma AI business cases must speak credibly to four distinct audiences in the executive committee. Each cares about different evidence, and a case that satisfies one will often fail another if it doesn’t address the relevant concerns explicitly.

Strong business cases address all four audiences in distinct sections. Weak cases assume one audience speaks for the others, or treat regulatory and operational concerns as appendices to a finance-led story.

Metrics That Land — and Metrics That Sink Cases

The metric you choose to anchor a business case signals what kind of investment you’re proposing. Some metrics open the door. Others close it before the conversation begins.

Metrics that build credibility

• Cycle time reduction with a clear definition of the cycle and a realistic baseline.
• Decision quality improvement measured against a defensible benchmark (review accuracy, signal detection rate, compliance variance).
• Risk-adjusted economic value, not just gross dollars saved.
• Capacity reallocation — what your people will do with the time recovered, not just that time is recovered.
• Audit-readiness uplift — measurable improvement in inspection preparation time or finding rates.

Metrics that sink cases

• FTE reduction as the primary economic story. In pharma, this is rarely the real win, and presenting it that way creates organizational resistance that outweighs the financial benefit.
• Generic productivity gains (“20% faster”) without operational context.
• Vendor-supplied benchmarks presented as evidence rather than reference points.
• Ratios without absolute numbers (“3x improvement” on a process that was already fast).
• Total addressable market figures imported from industry reports without organization-specific context.

Risk Framing for Regulated Environments

One of the cultural challenges of pharma AI investment is that risk framing varies wildly by function. Technology teams describe risk in terms of failure modes and mitigations. Quality describes risk in terms of validation effort and regulatory exposure. Finance describes risk in terms of probability-weighted economic loss. A business case that uses one of these frames exclusively will land flat with the other audiences.

The strongest cases use a layered risk framing that addresses each audience’s natural language. Below is a structure Sakara Digital recommends for AI use cases in regulated workflows.

Each layer should appear explicitly in the business case, with a paragraph or two describing the risk, its quantification, and the mitigation. Cases that treat risk as a single section rarely satisfy the multiple audiences whose sign-off is required.

Choosing the Right Comparisons

Most AI business cases compare the proposed AI use case to the current manual or system-supported process. That comparison is necessary but rarely sufficient at the executive level. The executive comparison set is broader.

An executive deciding whether to fund your AI use case is implicitly comparing it to:

• Other AI use cases competing for the same budget envelope
• Non-AI improvements to the same process (Lean, automation, restructuring)
• Doing nothing — accepting the status quo and reallocating budget elsewhere
• Outsourcing or process redesign as alternative paths to the same outcome

Strong business cases acknowledge this comparison set explicitly and explain why the AI investment is preferable. Weak cases treat the AI as the only option on the table, which signals to the executive committee that the business case is partial.

A Practical Business Case Template

The template below is the structure we recommend for executive-grade AI business cases in pharma and biotech. Each section addresses a specific question and a specific audience. Total length should be 12-18 pages for a substantive use case.

1. Executive summary (1 page)

The use case in one paragraph. The proposed investment. The expected return with sensitivity range. The recommendation.

2. Strategic context (1-2 pages)

Why this use case, why now. Connection to broader strategy (AI roadmap, digital transformation priorities, regulatory posture). Where it fits in the portfolio of AI investments.

3. Use case definition (2-3 pages)

The current process, the proposed AI-enabled process, the specific decisions or outputs the AI contributes to. Risk tier classification. Stakeholder map.

4. Economic model (2-3 pages)

Cost components: implementation, validation, ongoing operations, change management. Benefit components: cycle time, decision quality, capacity reallocation, audit readiness. Sensitivity analysis on the three biggest assumptions.

5. Risk and validation (2 pages)

Five-layer risk analysis (use case classification, validation approach, operational risk, economic risk, regulatory risk). Mitigation plan for each.

6. Implementation plan (1-2 pages)

Phased rollout with clear gates. Change management approach. Capacity and resource requirements. Critical dependencies.

7. Comparison and alternatives (1 page)

Explicit comparison to alternative investments and non-AI approaches. Why this option is preferable.

8. Recommendation and decision request (1 page)

What you’re asking for. Specific gates and approval points. What success at six and twelve months looks like.

Common Traps to Avoid

• Vendor-led business cases. If your business case borrows heavily from vendor-supplied materials, the executive committee will recognize it. Internalize the case before presenting.
• The “AI for AI’s sake” framing. Lead with the business problem, not the technology. The AI is the proposed solution, not the goal.
• Underestimating change management. Pharma AI deployments routinely underestimate the time and investment required to land the change with affected functions. Budget for it explicitly.
• Optimistic ramp curves. AI value typically does not appear until 6-9 months post-deployment in regulated environments. Cases that show benefits in month one fail credibility tests.
• Missing the validation cost. Tier 3 use cases carry significant validation overhead that should be a line item in the economic model, not an asterisk.

Closing Thoughts and Next Steps

A well-constructed AI business case is, in many ways, a stronger artifact than the AI implementation itself. It forces the organization to clarify the problem, the comparators, the risks, and the success criteria before committing capital. The cases that survive executive scrutiny are not the ones with the most exciting technology — they are the ones with the most honest economics.

If you are building a case in the next quarter, start with the executive personas and work backward. Identify what each one needs to see, draft the relevant sections, and stress-test them with internal reviewers before submission. The cases that get funded are usually the ones that have already been challenged and improved before they reach the steering committee.

References